Amy Lew Tsuhako

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Kyung Hae Jung, Patricia LoRusso, Howard A. Burris et al. · Clinical Cancer Research · 2019 · 281 citations · Full text

Discovery of XL413, a potent and selective CDC7 inhibitor

Elena S. Koltun, Amy Lew Tsuhako, David S. Brown et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 90 citations · Full text

Medicinal Chemistry, Drug Target, Selective Cdc7 Inhibitor +5

The design, synthesis, and biological evaluation of PIM kinase inhibitors

Amy Lew Tsuhako, David S. Brown, Elena S. Koltun et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 37 citations · Full text

Medicinal Chemistry, Pharmaceutical Science, Biochemistry +10

The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors

Moon H. Kim, Amy Lew Tsuhako, Erick W. Co et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 28 citations · Full text

Medicinal Chemistry, Drug Target, Biochemistry +10

A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS

Christopher H. Lieu, Manuel Hidalgo, Jordan Berlin et al. · The Oncologist · 2017 · 28 citations · Full text